


WEBINARS: CLINICAL EDUCATION ON YOUR SCHEDULE

CLINICAL APPLICATION OF ACCESS HIGH SENSITIVITY TROPONIN I IN THE EMERGENCY DEPARTMENT



Biomarkers complement clinical assessment and 12-lead ECG in the diagnosis, risk stratification, and treatment of patients with suspected NSTEMI-ACS. Measurement of a biomarker of cardiomyocyte injury, preferably high sensitivity cardiac troponin, is mandatory in all patients with suspected NSTEMI-ACS (2020 ESC Guidelines).

Join our expert, Professor Louise Cullen, as she discusses key aspects of implementation of change to maximize the clinical benefits of high sensitivity troponin I (hsTnI) as well as the impact of introduction of hsTnI on health services.

Speaker: Professor Louise Cullen

Department of Emergency Medicine
Royal Brisbane and Women's Hospital
Queensland, Australia



This webinar is organized under the auspices of
Asian-Pacific Federation for Clinical Biochemistry (APFCB)



ASIA-PACIFIC FEDERATION FOR CLINICAL BIOCHEMISTRY
AND LABORATORY MEDICINE



<http://www.webcasting.com.cn/beckman/Page.asp?id=73>